Cellectis Buries the CAR-T and Bets the Company on One Injection
A 70% headcount cut, two in vivo editing programs and $149 million of runway: Cellectis trades a decade of allogeneic cell therapy for a lipid-lowering shot
CLLS · Earnings Call · 2026-11-13
The pivot nobody on the old calls was ever asked about
For roughly three years, Cellectis Q&A sessions were a closed loop. Analysts asked about the bar for success in relapsed/refractory ALL, about whether alemtuzumab mattered more than Allogene's ALLO-647, about the Servier arbitration, and about what would be disclosed at the October R&D Day. The company's own keyword board confirmed the fixation: in the second quarter of 2025 the single highest-momentum phrase on the Cellectis call was R&D Day, with lasme-cel and arbitration with Servier close behind. On this call, none of it exists. Not the R&D Day, not the pivotal study design, not the arbitration. Instead, an analyst asked whether APOC3 or ANGPTL3 was the better target, and another asked whether the lipid nanoparticle had been used clinically before. The reason is simple: “Two months ago, we announced the strategic transformation of Cellectis into an in vivo gene editing company.” — André Choulika, Chief Executive Officer · 2026-11-13 The strategic transformation is not a re-weighting. It is an amputation. Both legacy allogeneic CAR-T programs — lasme-cel and eti-cel — were stopped, enrollment halted, sites closing, patients retained only on protocol follow-up. Global headcount is expected to fall by up to 70% from pre-transition levels across 2026 and 2027, subject to the French Works Council process. The vocabulary that once defined the company (alemtuzumab lymphodepletion, CD19 escape, off-the-shelf persistence) has been replaced by base editing, double strand break avoidance, and nuclease-free editors.Stopping the development of lasme-cel and eti-cel was not an easy decision. Behind these programs are patients and families, as well as the investigators and site teams who have been part of these programs over the years.
What the new company actually owns
Two assets, both liver-directed, both single-administration. HEAL-101 is a TALE-based editor making a single C-to-T conversion in the APOC3 gene, creating a stop codon without cutting DNA. The preclinical package presented at ESGCT in October showed roughly 90% editing in a human hepatic cell line, a mean ~65% (up to 70%) in a humanized liver mouse, and a 76% triglyceride reduction in a hypertriglyceridemic transgenic model. The safety claim is the tissue-selectivity claim: “editing was detected in the liver with no significant editing detected in the other tissues analyzed.” — Adrian Kilcoyne, Chief Medical Officer · 2026-11-13 An investigator-initiated trial in China starts in the first quarter, with preliminary clinical data guided to the second half of 2027. HEAL-201 targets PCSK9 with an epigenetic silencer rather than a cutter — above 90% on-site editing in human hepatic cell lines and over 90% mean plasma PCSK9 reduction in a humanized liver mouse. Phase I is being prepared; first data are guided to the first half of 2028. The target choice is the most interesting strategic argument on the call. Management ran market research across cardiologists, endocrinologists and internists and concluded, per the CMO, that “APOC3, in terms of specifically targeting triglycerides, was still superior to ANGPTL3 in that regard.” — Adrian Kilcoyne, Chief Medical Officer · 2026-11-13 The company is deliberately not chasing a dual lipid-lowering label — it wants the pancreatitis-risk population, where the clinical threshold is concrete (get patients under 500 mg/dL and the acute risk essentially disappears). The addressable pool is put at roughly 1.1 million patients across the U.S. and EU5.The arithmetic of a one-shot drug — and of a 70% smaller company
Cash, equivalents, restricted cash and term deposits stood at $149 million on 30 September, down from $211 million at year-end 2025. The $62 million drain was ordinary and unglamorous: $37.9 million to suppliers, $37.5 million of payroll and social charges, $7.3 million of lease payments, a $4.0 million PGE repayment, partly offset by $21.4 million collected from customers. The stated runway extends into the second half of 2028 — deliberately past both readouts: “once our realignment is fully implemented as planned, we will have a cash runway into the second half of 2028.” — Arthur Stril, Unknown (likely Investor Relations or Finance based on context) · 2026-11-13 That is a meaningful shift in the credibility of Cellectis' runway language. On the August 2025 call, the same CFO hedged a mid-2027 runway around pivotal CAR-T studies: “the cash runway into H2 2027 does include pivotal studies.” — Arthur Stril, Interim Chief Financial Officer · 2025-08-05 The company has habitually discounted partner cash — and it has now chosen a runway that does not depend on the cell-therapy machine it just shut down. The income statement is messy by design. Nine-month revenue and other income fell to $19.9 million from $67.4 million, almost entirely because less work was performed under the AstraZeneca research plans. R&D rose to $108.8 million from $69.1 million, but $34.9 million of that is the transformation itself — a $26.6 million one-off impairment, $6.2 million of termination benefits, $2.1 million of closeout costs. Strip those out and R&D grew about $4.8 million. Net financial result flipped to a $5.2 million gain from a $25.6 million loss, driven by non-cash fair-value gains on the European Investment Bank warrants. The bull case lever nobody asks about is manufacturing economics.If durability truly runs to years rather than months, a one-shot therapy competes against chronic injectables on annual cost per patient, not on headline price.This is LNP, mRNA formulated in LNP, which is extremely cheap. The gross margin potential of these products is absolutely tremendous. Don't only think about the addressable market in terms of number of patients, but I think these therapies will unlock pricing and cost of goods opportunities.